Metabolic-dysfunction-associated fatty liver disease
Conditions
Interventions
health volunteers group:No
Group Patients with Metabolic-dysfunction-associated fatty liver disease:No
Group Overweight/obese patients with MAFLD:No
Group Lean/normal weight with metabolic dysfunction patients with MAFLD:No
Sponsors
Department of Gastroenterology, Shenzhen Hospital, Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily sign the informed consent; 2. Aged 18-70 years old; 3. The subjects are willing to collect and send samples in strict accordance with the sampling procedures; 4. (Only applicable to healthy volunteers in the first phase of the study) vital signs, physical examination, blood routine, blood biochemistry, urinalysis All measurements were within the normal range or abnormal but the researchers considered insignificant abnormalities, and the body mass index was 19.0-23.0kg/m2 (including the cutoff value, calculation formula = weight/height 2), waist circumference =23kg/m2; (2) History of type 2 diabetes or fasting blood glucose >=7.0mmol/L; (3) Metabolic dysfunction, with at least two of the following risk factors for metabolic abnormalities: 1) Waist circumference: Asian men and women >=90 and 80cm respectively; 2) Blood pressure: >=130/85mmHg or receiving blood pressure lowering drug treatment; 3) Blood triglyceride: >=150mg/dL (>=1.70mmol/L) or receive blood lipid-lowering drug treatment; 4) Plasma high-density lipoprotein cholesterol: male = 2.5; 7) Blood hypersensitivity C-reactive protein: >2mg/L; 6. (Applicable to MAFLD patients in the second phase of the study) Diagnosed by imaging, blood biomarkers/NAS activity score (NAS pathology scoring system) or liver histology, diagnosed with hepatic steatosis, and combined with one of the following conditions : (1) Overweight/obesity: BMI>=23kg/m2; (2) Metabolic dysfunction, with at least two of the following risk factors for metabolic abnormalities: 1) Waist circumference: Asian men and women >=90 and 80cm respectively; 2) Blood pressure: >=130/85mmHg or receiving blood pressure lowering drug treatment; 3) Blood triglycerides: >=150 mg/dL (>=1.70 mmol/L) or receiving lipid-lowering drugs; 4) Plasma high-density lipoprotein cholesterol: male = 2.5; 7) Blood high-sensitivity C-reactive protein: >2mg/L.
Exclusion criteria
Exclusion criteria: 1. Present chronic diseases that may interfere with the study data, including but not limited to chronic infection, any intestinal diseases or symptoms (including but not limited to symptoms such as constipation and diarrhea and diseases such as colitis, Crohn's disease, intestinal obstruction and intestinal tumor); 2. Severe acute illness that may interfere with study data occurred in the month prior to screening; 3. Cirrhosis; 4. (phase II study only) fatty liver disease with type 2 diabetes; 5. Those who had used antibiotics within 3 months before the study began; 6. Had consumed a large amount of alcohol within 1 week prior to fecal sample collection (& GT; 1000 ml beer or gt; 200 ml of white wine) or significant changes in eating habits (e.g. sudden intake of large amounts of meat, vegetarian or industrially processed foods); 7. Subjects considered unsuitable for the study by the researcher, such as poor mental health, poor compliance, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differential bacteria in the gut; | — |
Countries
China
Contacts
Public ContactZhu Ying
Shenzhen Hospital of Southern Medical University
Outcome results
None listed